Rationale: Mating type switching/sucrose non-fermenting (SWI/SNF) chromatin-remodeling complexes utilize either BRG1 or BRM as a catalytic subunit to alter nucleosome position and regulate gene expression. BRG1 is required for vascular endothelial cell (VEC) development and embryonic survival, whereas BRM is dispensable.
T
he Saccharomyces cerevisiae SWI/SNF (mating type switching/sucrose non-fermenting) complex was the first chromatin-remodeling complex to be characterized and consists of 11 subunits with a total molecular mass of 1 to 2 MDa. 1,2 SWI/SNF complexes have been evolutionarily conserved although mammals have approximately 21 subunits due to duplication and divergence events that occurred during vertebrate evolution. 3 Rather than having a larger-sized complex consisting of 21 subunits, mammals have a number of 9-to 12-subunit complexes with different combinatorial assemblies (up to nϭ288 in theory). 3, 4 Subunit composition can change within a cell lineage as it differentiates and is known to vary among different tissues. 4, 5 However, despite this subunit diversity, all mammalian SWI/SNF complexes identified thus far contain either BRG1 or BRM (brahma-related gene 1 and brahma, also known as SMARCA4 and SMARCA2, respectively) as a catalytic subunit with DNAdependent ATPase activity. 3, 4 Each complex also contains several core subunits (also known as BRG1/BRM-associated factors or BAFs) including BAF170, BAF155, and BAF47 (also known as SNF5 or SMARCB1). 3, 4 SWI/SNF-related complexes are recruited by sequencespecific transcription factors to the promoters of numerous target genes, 6 -8 where they slide or evict histone octamers in an ATP-dependent manner. 9, 10 This alters the number and position of nucleosomes near transcriptional start sites to regulate RNA Polymerase II occupancy and transcriptional initiation. 10 -12 The importance of SWI/SNF complexes in mammalian development has been demonstrated by mouse knockout studies. Null mutations of Brg1, Baf250a/Arid1a, Baf155, and Baf47/Snf5 each confer peri-implantation lethality. 4, 13 This phenotype is consistent with the OCT4, SOX2, and Nanog pluripotency transcription factors recruiting a specific SWI/SNF subcomplex, called esBAF, to target genes in embryonic stem (ES) cells to facilitate their self-renewal and pluripotency. 7,14 -16 Null mutations of the Baf180 and Baf60c noncore subunits each result in midgestation lethality due to cardiac defects. 17, 18 Baf250a/Arid1a null heterozygotes and Brg1 conditional mutants also exhibit cardiovascular defects that are lethal at midgestation. 19 -21 At a mechanistic level, Brg1 genetically interacts with Tbx5, 21 and the BAF60c subunit facilitates a physical interaction between BRG1 and the cardiogenic transcription factors TBX5, GATA4, and Nkx2-5. 17 Furthermore, a combination of BAF60c plus TBX5 and GATA4 can program noncardiac mesoderm into cardiomyocytes. 22, 23 Based on these studies, SWI/SNF complexes have emerged as key epigenetic regulators of cardiomyocyte development. 22 Cardiomyocyte development is coordinated with vascular development, and Brg1 is also required for vasculogenesis, based on the midgestation lethality of Brg1
Tie2-Cre conditional mutants in which Brg1 was mutated in vascular endothelial cells (VECs) during embryogenesis. 24 -26 The Brg1
Tie2-Cre mutant phenotype was not exacerbated by Brm deficiency, 25 which is surprising because Brm is expressed at high levels in the developing vasculature and encodes a protein that is 75% identical to BRG1 with similar or identical chromatinremodeling properties on nucleosome arrays in cell-free systems. 27, 28 This finding suggests that VECs may rely on the PBAF class of complexes, which utilize only BRG1 as their catalytic subunit, rather than the BAF class that utilizes either BRG1 or BRM. 3 This possibility has a precedent as the esBAF subcomplex utilizes BRG1 exclusively as a catalytic subunit. 7, 14 Alternatively, BRG1 vascular function may occur in the context of BAF complexes, but BRM cannot compensate either because it interacts with different transcription factors and is recruited to different target genes or it has different biochemical properties than BRG1 in vivo. 8 Support for this possibility comes from the observation that the two catalytic subunits have antagonistic roles in the differentiation of certain cell lineages. 29 Regardless of which possibility proves correct, BRG1 and BRM clearly have distinct functions. In fact, the function of BRM is different than all other SWI/SNF subunits that have been knocked out thus far because Brm Ϫ/Ϫ mice are viable and fertile instead of being embryonic lethal. 4, 13, 30 Although BRG1-catalyzed SWI/SNF complexes are essential for cardiovascular development and other aspects of embryogenesis, 4, 13 it is not known whether they maintain cellular homeostasis after development is complete. To address this important issue, it was necessary to circumvent the requirement for Brg1 during embryogenesis; therefore we used the inducible Mx1-Cre driver to mutate Brg1 in several tissues of adult Brg1 fl/fl mice. By analyzing these conditional mutants on both wild-type and Brm-deficient backgrounds, we discovered an unprecedented genetic interaction between Brg1 and Brm in cardiovascular homeostasis as described below.
Methods
An expanded Methods section is available in the Online Data Supplement.
All mouse experiments were approved by the Institutional Animal Care and Use Committee (IACUC) review board at the University of North Carolina and were performed in accordance with federal guidelines. The Brg1 floxed and ⌬ floxed alleles and the Brm mutation were genotyped by PCR as previously described. 30, 31 To induce Mx1-Cre in vivo, mice were injected intraperitoneally with 300 mg of pI-pC (Sigma, St Louis, MO) dissolved in PBS in a volume of 0.2 cc. Mice were injected every other day for a total of 5 treatments. Control mice received the same injection regimen but with PBS only.
Histology was performed by fixing heart and other tissues in 4% paraformaldehyde, embedding in paraffin, and cutting 5-m sections according to standard procedures. Sections were either stained with hematoxylin and eosin or processed for immunohistochemistry (IHC), using a BRG1 rabbit polyclonal antibody (Upstate/Millipore No. 07-478, Temecula, CA) or a platelet endothelial cell adhesion molecule (PECAM)-1 antibody (Upstate/Millipore No. 04 -1074) according to the manufacturer's recommendations. X-Gal staining was performed using standard procedures on 200-m vibratome slices of heart and other tissues from Rosa26 reporter (R26R, Rosa-lox-stop-lox-LacZ) mice carrying the Mx1-Cre transgene.
For electron microscopy, after perfusion with 2% paraformaldehyde and 2.5% glutaraldehyde in 0.15 mol/L sodium phosphate buffer (pH 7.4), heart and other tissues were fixed in the same solution overnight and then postfixed with 1% osmium tetroxide/ 0.15 mol/L sodium phosphate buffer. Samples were dehydrated with increasing concentrations of ethanol, infiltrated and embedded in Polybed 812 epoxy resin (Polysciences, Warrington, PA), and 70-nm ultrathin sections were cut with a diamond knife. Sections were mounted on 200-mesh copper grids and staining with 4% aqueous uranyl acetate and Reynolds lead citrate. Sections were observed with a LEO EM910 transmission electron microscope operating at 80 kV (LEO Electron Microscopy, Thornwood, NY) and photographed with a Gatan-Orius SC1000 CCD Digital Camera and Digital Micrograph 3.11.0 (Gatan, Pleasanton, CA).
Primary VECs were isolated and cultured as described with minor modifications. 32 Transthoracic echocardiography was performed on conscious mice using a VisualSonics Vevo 770 ultrasound biomicroscopy system (VisualSonics, Inc, Toronto, Ontario, Canada) with a 30-MHz 707B scan head as previously described. [33] [34] [35] Twodimensionally guided M-mode analysis of the left ventricle was performed in a genotype-blinded fashion in the plane of the parasternal long axis at the level of the papillary muscle. Epicardium and endocardium leading edges were used to the measure the anterior and posterior wall thickness (IVSTD, IVSTS), posterior wall thickness (PWTD, PWTS), and left ventricular internal diameters (LVEDD, LVESD). Left ventricle (LV) volume in diastole (LV VolD) was calculated from the equation LV VolDϭ(7/ 2.4ϩLVEDD)ϫLVEDD 3 ϫ1000, and LV volume in systole (LV VolS) was calculated from the equation LV VolSϭ(7/ 2.4ϩLVESD)ϫLVESD 3 ϫ1000. Left ventricular systolic function was assessed by ejection fraction (EF), calculated from the equation EF%ϭ(LV VolDϪLV VolS)/LV VolDϫ100, and fractional shortening (FS), calculated from the equation FS%ϭ (LVEDDϪLVESD)/ LVEDDϫ100. M-mode measurements represent 3 average consecutive cardiac cycles from each mouse.
Results

Functional Compensation of Brg1 and Brm
To investigate the role of Brg1 in adult tissues, we crossed previously characterized Mx1-Cre transgenic mice and Brg1 floxed mice to generate Brg1 conditional null homozygotes (Brg1 fl/fl ; Mx1-Cre ϩ/0 ). 31, 36 Because Mx1-Cre is inducible, Cre is not expressed and the floxed-to-⌬floxed excision does not occur until after the mice have been injected with polyinosinic-polycytidylic acid (pI-pC), a synthetic doublestranded RNA that activates the interferon-responsive Mx1 promoter. 36 Previous studies of Mx1-Cre using Rosa26 reporter (R26R) mice have demonstrated that pI-pC treatment results in Cre-mediated excision in the following cell types: hematopoietic stem cells and their descendants, hepatocytes, VECs throughout the body, the gastric epithelium, kidney (collecting ducts, glomeruli, and renal vascular endothelium), and smooth muscle in a subset of organs. 36, 37 Therefore, each of these cell types will be functionally null in our Brg1 conditional null homozygotes after pI-pC treatment. To assess excision of the Brg1 locus, we performed PCR on tissues from Brg1 fl/fl ; Mx1-Cre ϩ/0 mice. We detected the Brg1 ⌬floxed PCR product in mice that were treated with pI-pC but not in control mice that were treated with vehicle (PBS) or that were untreated ( Figure 1A ). These results confirmed that the Brg1 excision event was induced by pI-pC as expected.
We administered either pI-pC or PBS to 3 categories of mice at 5 to 7 weeks of age and monitored their health and survival. The first category consisted of 40 control mice divided into 4 subcategories: 1, Brg1 fl/fl mice lacking the Mx1-Cre transgene that were treated with pI-pC (nϭ10); 2, Brg1 fl/fl mice lacking the Mx1-Cre transgene on a Brm
background that were treated with pI-pC (nϭ10); 3, Brg1 conditional null homozygotes (Brg1 fl/fl ; Mx1-Cre ϩ/0 ) that were treated with PBS (nϭ10); 4, Brg1 conditional null homozygotes on a Brm Ϫ/Ϫ background that were treated with PBS (nϭ10). Brg1 was not mutated in any of these control mice, and each animal was healthy and had normal survival as expected ( Figure 1B ). The second category comprised 25 single mutants: Brg1 conditional null homozygotes on a wild-type (nϭ15) or Brm Ϯ (nϭ10) background that were treated with pI-pC (herein referred to as Brg1
Mx1-Cre single mutants). All of these animals were also healthy and had normal survival ( Figure 1B ) and a normal lifespan (26Ϯ5 months). The third category was double mutants: Brg1 conditional null homozygotes on a Brm Ϫ/Ϫ background that Ϫ/Ϫ background that were treated with PBS (nϭ10). Single mutants: Brg1 conditional null homozygotes on a wild-type (nϭ15) or Brm Ϯ (nϭ10) background that were treated with pI-pC. Double mutants: Brg1 conditional null homozygotes on a Brm Ϫ/Ϫ background that were treated with pI-pC (nϭ15).
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were treated with pI-pC (nϭ15). These mice (herein referred to as Brg1 Mx1-Cre /Brm Ϫ/Ϫ double mutants) either died or had to be euthanized within one month of pI-pC treatment due to their moribund condition (eg, hunched posture, lethargy, labored breathing, and reduced response to direct contact) ( Figure 1B ). This phenotype was 100% penetrant as all 15 Brg1
Mx-Cre /Brm Ϫ/Ϫ double mutants became moribund. These results indicate that the Brg1 and Brm catalytic subunits functionally compensate in the Mx1-Cre model.
Brg1
Mx1-Cre
/Brm ؊/؊ Double-Mutant Mice Exhibit Cardiac Defects and Ventricular Dissections
To begin to understand the cause of death, Brg1
Mx1-Cre / Brm Ϫ/Ϫ double mutant mice were euthanized 20 to 30 days after pI-pC treatment, while they were moribund. Pleural effusions were present in nearly all mice, characteristically being a clear to blood-tinged fluid. Gross examination of these mice also revealed a kidney phenotype consistent with medullary congestion (Online Figure IA) . Other organ systems, including the liver and gastrointestinal tract, were unremarkable on gross inspection and indistinguishable from control mice.
Since pleural effusions can be associated with cardiac defects such as heart failure, we first analyzed the hearts and lungs from Brg1
Mx1-Cre /Brm Ϫ/Ϫ double mutants that had been treated 20 to 30 days earlier with pI-pC. Unlike control hearts (Figure 2A ), numerous extravascular erythrocytes were identified within the myocardial interstitium of the atria and throughout the left and right ventricular myocardium from the apex to the base of double-mutant hearts ( Figure 2B ). This hemorrhage was particularly evident in the outer myocardium (representative sections shown in Figure 2B ), whereas the endocardium and valve endothelium appeared normal at this level of magnification. Whereas the structural integrity of the aortic root, pulmonary artery, and coronary arteries remained intact (data not shown), we observed the subepicardial microvasculature as the primary source of the multifocal hemorrhages into the interstitium ( Figure 2B ). Brg1 Mx1-Cre / Brm Ϫ/Ϫ double-mutant hearts also exhibited areas of necrotic cardiomyocytes, a subset of which showed dystrophic calcification, scattered diffusely throughout the hemorrhagic myocardium ( Figure 2B and Online Figure II) , and this was associated with myocardial dissections identified by 2D echocardiography ( Figure 2C ). There were acute and chronic inflammatory cells within the affected myocardium, as well as reactive fibroblasts in areas with chronic cardiomyocyte injury (data not shown). Based on the analysis of Masson trichrome-stained sections, Brg1
Mx1-Cre /Brm Ϫ/Ϫ doublemutant hearts also had significant fibrosis (Online Figure II) Figure 2. Histopathologic and 2D echocardiographic findings in Brg1/ Brm double-mutant hearts. Representative images of hematoxylin and eosinstained heart sections from a control (A) and double-mutant (B) mice 25 days after pI-pC treatment. Animal numbers are indicated. The double-mutant hearts have diffuse and focal interstitial hemorrhage associated with myocyte necrosis (arrows) and calcification (arrowheads), particularly in the outer myocardium, which may result in myocardial dissection (C). Asterisk denotes artifactual disruption of ventricular wall due to fixative perfusion needle insertion. C, Images extracted from 2D video outlining the anterior wall (top) and posterior wall (bottom) cardiac dissections identified after pI-pC treatment (see Online Table  I ). The 2D video files are included (indicated in 2D image itself) in the Online Data Supplement. LA indicates left atria. Asterisk denotes area of dissection on day before death; 56% of mice had detectable dissections on mean day 38.8Ϯ9.9 (detailed in Online Table I ).
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and cardiomyocyte hypertrophy (Online Figure IIIA) . Quantification of cardiomyocyte cross-sectional areas revealed a 1.6-fold increase in double mutants compared with controls (Online Figure IIIB) . In contrast to the heart, we did not detect any histopathologic abnormalities or abnormal cell death in the lungs or kidneys from Brg1 Mx1-Cre /Brm Ϫ/Ϫ double-mutant mice (Online Figure I) . To more carefully define the cardiac phenotype and provide insight into the kinetics of disease progression, we conducted a longitudinal echocardiographic study. After pI-pC treatment, we performed daily transthoracic echocardiography on 9 conscious Brg1
Mx1-Cre /Brm Ϫ/Ϫ double mutants until each animal died or was euthanized due to humane endpoints. We also longitudinally analyzed 6 sibling-matched controls: 3 Brg1
Mx1-Cre /Brm Ϫ/Ϫ double mutants that were not treated with pI-pC and 3 Brg1 fl/fl , Brm Ϫ/Ϫ mice lacking the Mx1-Cre transgene that were treated with pI-pC. On the first day of echocardiography (on the day after the final pI-pC treatment corresponding to day 9 in Figure 1B ), we did not detect any significant differences for 15 quantitative measurements, referred to as "baseline," between the treated double mutants and the 2 control groups ( Figure 3A and the Table) .
On subsequent echocardiographic studies, we detected an increased thickness of the anterior or posterior left ventricular wall of treated double mutants between 7 and 21 days later (median of 14 days) (Online Figure IV and Online Table I ). In contrast, ventricular wall measurements did not change over time in any of the control mice (Online Figure IV) . The left ventricular wall of the treated Brg1
Mx1-Cre /Brm Ϫ/Ϫ double mutant mice became progressively thicker over time (Online Figure  IV) . On the final echocardiogram, acquired 1 day before their death [(ie, premortem) median of 25 days after first echocardiogram (Online Table I 
/Brm
Ϫ/Ϫ double mutant mice was nearly twice that of controls ( Figure 3A and the Table) . For example, the anterior wall thickness in diastole was 1.84Ϯ0.11 mm in treated double mutants compared with 1.04Ϯ0.04 mm and 1.06Ϯ0.02 mm in the 2 control groups ( Figure 3A and the Table) . In addition to increased ventricular wall thickness, treated double mutants had a significant 2.4-fold increase in their left ventricular mass/body weight ratio and a 42% decrease in heart rate the day before their death ( Figure 3A and the Table) .
In addition to the changes identified in wall thickness, a number of additional progressive cardiac defects were seen in 
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the Brg1 Mx1-Cre /Brm Ϫ/Ϫ double mutants. We consistently observed pericardial and intracardiac fluid accumulation in both 2D and M-mode echocardiography ( Figure 3B ). The intracardiac fluid was associated with dissections of the anterior or posterior ventricular wall (Online Movies). We observed dissections in 56% of the treated double mutants, and they preceded death by 3 to 7 days with a median of 5 days (Online Table I 
Cardiac Vascular Endothelial Cell Death Is the Primary Defect
To identify the primary cellular defect in the heart of Brg1
Mx1-Cre /Brm Ϫ/Ϫ double mutants, it was necessary to determine where BRG1 is normally expressed in the heart and cardiomyocytes (white arrow) from a control mouse heart. B, X-Gal staining of a representative heart section from pI-pC-treated R26R mice carrying the Mx1-Cre transgene. Strong staining (blue) occurred in VECs such as those enclosed by dashed circle, but staining was absent in cardiomyocytes as exemplified by the arrows. C, No X-Gal staining occurred in heart sections from the same R26R mice carrying the Mx1-Cre transgene when they were not treated with pI-pC. D and E, IHC demonstrating PECAM-1 staining of VECs in heart sections from control (D) and Brg1/Brm double-mutant (E) mice. A continuous staining of VECs was observed within control vessels (D), whereas staining was discontinuous in double-mutant vessels (E). and where Mx1-Cre inactivates the floxed allele. Therefore, we performed IHC and discovered that BRG1 is normally expressed in both VECs and cardiomyocytes throughout the heart in a nuclear distribution ( Figure 4A ). Because Mx1-Cre activity has not been characterized in the heart, we crossed the Mx1-Cre transgene onto the R26R background and performed X-Gal staining on heart sections from these mice. Strong nuclear Cre activity was induced by pI-pC in VECs throughout the heart but not in the cardiomyocytes ( Figure  4B ). No Cre activity was detected in either cell type in control mice that either lacked the Mx1-Cre transgene or that were not treated with pI-pC as expected ( Figure 4C ). Therefore, although BRG1 is expressed in both VECs and cardiomyocytes within the heart, it is only mutated in VECs suggesting this is the primary cell type responsible for the cardiovascular phenotype in double mutants. We first investigated cardiac vascular endothelial cells by IHC using PECAM-1 (also known as CD31). A strong, continuous staining in vessels was identified in control mice ( Figure 4D ). In contrast, the cardiac vasculature of Brg1
Mx1-Cre
/
Brm
Ϫ/Ϫ double mutants had a discontinuous staining in moribund mice at 20 to 30 days after pI-pC administration ( Figure 4E ). This result suggested that a subset of endothelial cells within double-mutant hearts either no longer expressed PECAM-1, or were dead/absent. To distinguish between these possibilities, we performed transmission electron microscopy at 25 days after pI-pC treatment. Two distinct phenotypes were seen in these cells. The first distinguishing phenotype of the pI-pC-treated double mutants was the presence of dying endothelial cells attached to live VECs in the capillaries ( Figure 5A) . Notably, the gap junctions were intact between the dying and live VECs ( Figure 5A and 5B), as they were between live cells throughout the treated Brg1
Mx1-Cre /Brm Ϫ/Ϫ mutants and control mice. The second distinguishing feature of the pI-pC-treated double mutants is that they had variably thicker VECs with larger vesicles, compared with controls, including swollen mitochondria and rough endoplasmic reticulum ( Figure 5C ). Consistent with the histopathology seen in Figure 2 , capillaries with breached endothelium were identified in areas of hemorrhage and clot (data not shown). Many of these microvascular remnants had immune cell infiltration, platelets, and proteinaceous material consistent with fibrin clot formation. As expected, there was a correlation between the presence of injured and necrotic cardiomyocytes and sites of hemorrhage.
Consistent with VECs being the primary cell type-affected, it was the cell type in which we first observed a cardiac phenotype in Brg1
Mx1-Cre /Brm Ϫ/Ϫ double mutants at 
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earlier time points after the induction of the Brg1 mutation. For example, when we analyzed Brg1 Mx1-Cre /Brm Ϫ/Ϫ double mutants 14 days after the first dose of pI-pC, while they still appeared healthy and before any hemorrhage could be detected in hematoxylin and eosin-stained sections, the cardiomyocytes appeared normal, whereas the VECs were uniformly thickened with increased vacuolization (Figure 6B through 6D) compared with VECs found in control mice ( Figure 6A ). At this 14-day after the pI-pC time point, however, we did not identify any endothelial cells that were necrotic or absent. This phenotype was consistent with the thickened endothelial cells seen at the later time point (days 20 -30) shown in Figure 5A and 5B. Since we were unable to identify any necrotic or missing endothelial cells at day 14 but found them readily at days 20 to 30, this supports a model in which mutation of Brg1 and Brm in the VEC is the primary event, which leads to VECs undergoing physical changes at or before day 14 and VEC cell death by day 25. The distinct cardiac phenotype appears to be a secondary consequence of this localized VEC death resulting in intramyocardial hemorrhage, ischemia, cardiomyocyte death, and cardiac dissection.
To evaluate VEC survival/lethality in more detail, we used PECAM-1 magnetic bead sorting to isolate and culture primary VECs from the hearts of conditional mutant and control mice. These primary VECs had a characteristic cobblestone appearance and were PECAM-1-positive ex vivo, and their identity was confirmed by RT-PCR, since they were positive for the VEC markers VE-cadherin and FLK1/ VEGFR2 (Online Figure VI) . These same cells were negative for ␣-smooth muscle actin and FLT4/VEGFR3, which are pericyte and lymphatic endothelial cell markers, respectively (Online Figure VI) . Cultures were established from Brg1 fl/fl ; Mx1-Cre ϩ/0 mice on a Brm Ϫ/Ϫ background and nontransgenic controls (Brg1 fl/fl mice lacking the Mx1-Cre transgene on a Brm Ϫ/Ϫ background). However, none of the mice used in these experiments were treated with pI-pC so the VECs were functional for Brg1 at the time of their derivation. Cells were then treated with pI-pC for 3 successive days, and cell number was monitored over a 2-week period. Relative to day 0 (immediately before the first pI-pC treatment), the number of VECs from Brg1 fl/fl ; Mx1-Cre ϩ/0 ; Brm Ϫ/Ϫ mice (double mutants) dropped to 70% at day 7 and then to 10% at day 14 ( Figure 7A ). In contrast, VECs from the same mice that were not treated with pI-pC ex vivo survived and proliferated increasing to 180% and 350% at days 7 and 14, respectively ( Figure 7A ). When a BRG1 cDNA expression vector was introduced into these cells, it rescued the drop in cell number after pI-pC-induced deletion of the endogenous Brg1 locus ( Figure 7A ). As a final control, the number of VECs from nontransgenic control mice increased to a similar extent regardless of whether or not they were treated with pI-pC as expected ( Figure 7A ). These results demonstrate that the VEC phenotype is cell autonomous and occurs under normoxic conditions.
After pI-pC treatment, the observed decrease in the number of double-mutant cells could be due to decreased cell proliferation and/or increased cell death. To distinguish between these possibilities, we performed BrdU incorporation, Annexin V, and propidium iodide assays. We did not observe a significant difference between double mutants and nontrans- genic controls for BrdU incorporation ( Figure 7B ) but did observe a significant difference for Annexin V and PI staining ( Figure 7B ). These findings indicate that the drop in cell number ex vivo arises because of increased apoptosis and cell death rather than decreased cell proliferation, and this is consistent with the cell death observed in vivo. Also similar to the in vivo phenotype, the cell death that occurred ex vivo resulted in permeability defects based on permeability assays that measured the movement of FITC-dextran macromolecules through a monolayer of VECs cultured on transwell inserts. The barrier function of double-mutant cells was intact 1 day after pI-pC treatment but was compromised 7 days after pI-pC treatment ( Figure 7C ). To determine whether this phenotype is associated with a perturbation in canonical SWI/SNF function, we analyzed the expression of genes that are expressed in endothelial cells and are regulated by BRG1-catalyzed SWI/SNF-related complexes. Accordingly, RT-qPCR showed a significant decrease in the mRNA levels 
Consequences of Vascular Permeability Defects
The occurrence of vascular permeability defects in Brg1
Mx1-Cre / Brm Ϫ/Ϫ mutants might be expected to result in increased platelet activation and clot formation. Indeed, ELISA assays demonstrated that plasma samples from Brg1
Mx1-Cre /Brm Ϫ/Ϫ mutant mice 30 days after their first pI-pC treatment had elevated levels of platelet activation factor (PAF) and thrombin compared with controls (Online Figure VIIA and B) . Platelets isolated from the double-mutant mice were less reactive to collagen in aggregation assays (Online Figure  VIID) , which is consistent with a previous exposure to collagen as a result of compromised vessels. Platelets are consumed during the clotting process so thrombocytopenia might also be expected, and complete blood counts showed that Brg1 Mx1-Cre /Brm Ϫ/Ϫ mutant mice had lower numbers of platelets 30 days after the first pI-pC treatment compared with controls (Online Figure VIIE) . Finally, one might also expect VEGF levels to be increased in an attempt to compensate for the loss of VECs, and ELISA assays demonstrated that this was the case (Online Figure VIIC) . Taken together, these secondary effects are consistent with severe vascular permeability defects.
Discussion
Because SWI/SNF complexes are essential for embryonic development, we do not know whether they are required for cellular homeostasis in adults. To address this issue, we utilized the inducible Mx1-Cre driver to mutate the Brg1 catalytic subunit in various tissues of adult mice. These conditional mutants exhibited extensive cell death in cardiac tissue but not in other cell types that were also mutated such as the hematopoietic lineages and hepatocytes. The tissue specificity of this cardiovascular phenotype is consistent with previous studies demonstrating that BRG1-catalyzed SWI/ SNF complexes play a particularly important role in cardiovascular development in utero, 17-21,24 -26 but there is an important difference regarding redundancy. Previous studies have shown that BRM does not compensate for BRG1 in either cardiomyocytes or VECs during embryonic development, 20, 21, 25 whereas our data clearly demonstrate that BRM does compensate in VECs of adults. This difference suggests that only BRG1-catalyzed complexes function in the establishment of VEC lineages during embryogenesis, whereas both BRG1-and BRM-catalyzed complexes function in the maintenance of differentiated VECs in the adult.
The Mx1-Cre driver mutated Brg1 in VECs within the heart but not in cardiomyocytes. Consequently, VEC death was the primary defect, which resulted in vascular leakage, hemorrhage, ischemia, and cardiomyocyte death as a secondary effect. The VEC phenotype was most evident in the microvasculature, which is relatively fragile because it lacks the structural support that larger vessels receive from surrounding smooth muscle and adventitia. Furthermore, the hemorrhages were almost entirely confined to the heart, somewhat favoring the epicardium more than the endocardium, despite the fact that the Mx1-Cre driver targets VECs throughout the body. This organ and regional specificity may be attributed to the cardiac microvasculature being exposed to the physical forces associated with heartbeat compared with other organs. In support of this idea, we observed ultramicroscopic changes in double-mutant tongues, which are also subjected to physical forces in rodents due to their licking and grooming behavior (Online Figure VIII) . Notably, the double mutants had a marked increase in the number and size of vesiculo-vacuolar organelles, which are associated with enhanced endothelial cell permeability (Online Figure VIII) . 41 We would expect to observe hemorrhages in other organs if the double mutants did not die of their cardiovascular defects and survived longer.
Vascular dissections have been studied most prominently in the aorta. When vascular dissections extend into the heart itself, there is a characteristic decrease in contractility, as seen in the present study. Recent studies have shown that an underlying cause of vascular dissections is the induction of apoptosis of smooth muscle cells in the aortic artery, which leads to the degradation of the media. 42 Recent clinical and basic research demonstrates that there is an inflammatory component to these dissections, which may initiate apoptosis. 43 The present study links endothelial cell death with cardiac dissections, which are generally extensions of aortic root dissections in humans. To our knowledge, Brg1 and Brm are the first genes shown to protect against cardiac dissections. The cardiac VEC death observed in vivo was recapitulated in primary cells ex vivo. This finding demonstrates that VEC death due to loss of Brg1/Brm is cell autonomous and occurs under normoxic conditions (ie, VEC death was not secondary to vascular leakage and ischemia).
In a previous study, we demonstrated that Brg1 ϩ/Ϫ mice developed mammary tumors, whereas Brg1 ϩ/Ϫ , Brm Ϫ/Ϫ mice developed mammary and VEC (ie, hemangiosarcoma) tumors. 44 This difference in tumor spectrum suggests that BRG1/BRM redundancy affects VEC homeostasis with respect to tumorigenesis in addition to cell viability. The finding that BRG1/BRM redundancy protects against oncogenic transformation instead of cell death in these mice is likely due to BRG1 dosage (ϩ/Ϫ versus Ϫ/Ϫ) and the accumulation of mutations in other genes that protect against cell death. Because mutations of genes encoding SWI/SNF subunits are common in certain types of human primary tumors, 45 it will be interesting to evaluate BRG1 and BRM for point mutations when human hemangiosarcomas undergo deep sequencing.
Finally, a negative result from this study has important mechanistic implications. Snf5
Mx1-Cre mutants exhibit a hematopoietic phenotype consistent with a hematopoietic stem cell defect, 46 Mx1-Cre mutants, we observed normal hematopoietic cellularity within bone marrow in hematoxylin and eosin-stained femur sections from Brg1
Mx1-Cre /Brm Ϫ/Ϫ double mutants (Online Figure IX) . We also performed flow cytometry and observed normal numbers of hematopoietic stem cells, common myeloid progenitors, and common lymphoid progenitors (data not shown). This finding suggests that hematopoietic stem cells require SWI/ SNF complexes but in a noncanonical manner that is dependent on SNF5 but is independent of either catalytic subunit. It is surprising because SWI/SNF function is usually equated with the BRG1 or BRM DNA-dependent ATPase activity that remodels nucleosomes. Essentially all SNF5 copurifies with SWI/SNF complexes, and it is not required for complex stability. 47, 48 Furthermore, SNF5 protects against cancer in a BRG1-dependent manner, 49, 50 which suggests that the mechanism of SWI/SNF action is fundamentally different during early hematopoiesis. It is not clear how SNF5 and the other BAF subunits contribute to SWI/SNF function at the biochemical level in cancer or during development, but they probably do more than simply serve as scaffolding factors that stabilize complexes or enhance canonical catalytic activity as demonstrated previously. 28 These subunits are known to participate in the recruitment and DNA binding of complexes to downstream target genes, which is usually viewed in an e120
Novelty and Significance
What Is Known?
• SWI/SNF chromatin-remodeling complexes are important for the development of cardiomyocytes and vascular endothelial cells during mammalian embryogenesis.
• The BRG1 catalytic subunit is required for vascular endothelial cell development, whereas the closely related alternative catalytic subunit, BRM, is dispensable.
• BRM does not compensate for BRG1, based on the observation that a Brg1 conditional mutation in mouse vascular endothelial cells is not exacerbated by Brm deficiency.
What New Information Does This Article Contribute?
• In contrast to developing vascular endothelial cells, genetic experiments showed that BRM does compensate for the loss of BRG1 in vascular endothelial cells of adult mice.
• The requirement for BRG1 and BRM in vascular endothelial cells of adult mice is most pronounced in the heart, particularly in the epicardium, which may be due to mechanical-physical stresses associated with heartbeat.
• Vascular endothelial cell death in the heart results in vascular leakage, ischemia, cardiomyocyte death, ventricular dissections, and lethality of Brg1/Brm double-mutant mice.
Based on gene-targeting experiments in mice, BRG1-catalyzed SWI/SNF complexes are required for many aspects of embryogenesis including cardiovascular development. However, because Brg1 mutants exhibit embryonic lethality, little is known about the role of BRG1 and SWI/SNF in the homeostasis of cells and tissues from adult mice. To circumvent this limitation, we used an inducible gene targeting approach to knockout Brg1 in various tissues of adult mice. These conditional mutant mice had a normal lifespan on a wild-type background but died within 1 month on a Brm-deficient background. Analysis of these double-mutant mice revealed a tissue-specific effect restricted to vascular endothelial cells, primarily within the heart, that was recapitulated using an ex vivo culture system. Vascular endothelial cell death in double mutants led to vascular leakage, ischemia, cardiomyocyte death, and ventricular dissections. These results demonstrate that Brm functionally compensates for Brg1 in vivo and that there are significant changes in the relative importance of BRG1-and BRM-catalyzed SWI/SNF complexes during the development of an essential cell lineage. 
